(PLRX) Pliant Therapeutics - Overview
Stock: Fibrosis, Bexotegrast, Liver, Muscular Dystrophy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 73.6% |
| Relative Tail Risk | -7.49% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.21 |
| Alpha | -108.99 |
| Character TTM | |
|---|---|
| Beta | 1.211 |
| Beta Downside | 1.334 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.60% |
| CAGR/Max DD | -0.70 |
Description: PLRX Pliant Therapeutics January 19, 2026
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a U.S. biotech focused on small-molecule integrin inhibitors for fibrotic and related diseases. Its lead asset, bexotegrast-a dual αvβ6/αvβ1 integrin blocker-has finished a Phase 2a trial in primary sclerosing cholangitis. The pipeline also includes PLN-1474 (αvβ1-selective for NASH-related liver fibrosis), PLN-101095 (dual αvβ8/αvβ1 for solid tumors), and a Phase 1-ready program (PLN-101325) targeting Duchenne muscular dystrophy and other muscular dystrophies.
Key quantitative context (as of the most recent filings): the company reports a market capitalization of roughly $250 million and cash and short-term investments of about $120 million, giving it an estimated 12-month cash runway at current burn rates. The global fibrosis therapeutics market is projected to grow at a CAGR of 7-8 % through 2030, driven by rising NASH prevalence and unmet needs in cholestatic liver diseases-both core targets for Pliant. Upcoming catalysts include a planned Phase 2b/3 read-out for bexotegrast in PSC and the initiation of a Phase 2 trial for PLN-1474 in NASH, events that could materially shift valuation.
For a deeper quantitative view, consider reviewing the analyst dashboard on ValueRay to explore Pliant’s risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -175.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -26.75 > 1.0 |
| NWC/Revenue: 10.0k% < 20% (prev 7646 %; Δ 2396 % < -1%) |
| CFO/TA -0.57 > 3% & CFO -158.2m > Net Income -175.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (61.4m) vs 12m ago 1.11% < -2% |
| Gross Margin: 10.57% > 18% (prev 0.56%; Δ 1001 % > 0.5%) |
| Asset Turnover: 0.63% > 50% (prev 1.09%; Δ -0.46% > 0%) |
| Interest Coverage Ratio: -32.59 > 6 (EBITDA TTM -168.5m / Interest Expense TTM 5.22m) |
Altman Z'' -15.00
| A: 0.82 (Total Current Assets 245.6m - Total Current Liabilities 17.6m) / Total Assets 276.6m |
| B: -3.02 (Retained Earnings -835.8m / Total Assets 276.6m) |
| C: -0.47 (EBIT TTM -170.3m / Avg Total Assets 361.1m) |
| D: -10.95 (Book Value of Equity -835.8m / Total Liabilities 76.3m) |
| Altman-Z'' Score: -19.12 = D |
Beneish M 0.66
| DSRI: 0.87 (Receivables 908.0k/2.22m, Revenue 2.27m/4.84m) |
| GMI: 5.29 (GM 10.57% / 55.97%) |
| AQI: 1.58 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.47 (Revenue 2.27m / 4.84m) |
| TATA: -0.06 (NI -175.5m - CFO -158.2m) / TA 276.6m) |
| Beneish M-Score: 0.66 (Cap -4..+1) = D |
What is the price of PLRX shares?
Over the past week, the price has changed by -5.79%, over one month by -10.94%, over three months by -25.49% and over the past year by -90.46%.
Is PLRX a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PLRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.3 | 185.1% |
| Analysts Target Price | 3.3 | 185.1% |
| ValueRay Target Price | 0.7 | -36.8% |
PLRX Fundamental Data Overview February 03, 2026
P/B = 0.3712
Revenue TTM = 2.27m USD
EBIT TTM = -170.3m USD
EBITDA TTM = -168.5m USD
Long Term Debt = 30.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 59.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.9m USD (from netDebt column, last quarter)
Enterprise Value = -107.6m USD (74.4m + Debt 59.9m - CCE 241.8m)
Interest Coverage Ratio = -32.59 (Ebit TTM -170.3m / Interest Expense TTM 5.22m)
EV/FCF = 0.68x (Enterprise Value -107.6m / FCF TTM -158.8m)
FCF Yield = 147.6% (FCF TTM -158.8m / Enterprise Value -107.6m)
FCF Margin = -6995 % (FCF TTM -158.8m / Revenue TTM 2.27m)
Net Margin = -7731 % (Net Income TTM -175.5m / Revenue TTM 2.27m)
Gross Margin = 10.57% ((Revenue TTM 2.27m - Cost of Revenue TTM 2.03m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.39 (set to none) (Enterprise Value -107.6m / Total Assets 276.6m)
Interest Expense / Debt = 4.65% (Interest Expense 2.78m / Debt 59.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -134.5m (EBIT -170.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.93 (Total Current Assets 245.6m / Total Current Liabilities 17.6m)
Debt / Equity = 0.30 (Debt 59.9m / totalStockholderEquity, last quarter 200.3m)
Debt / EBITDA = 0.20 (negative EBITDA) (Net Debt -33.9m / EBITDA -168.5m)
Debt / FCF = 0.21 (negative FCF - burning cash) (Net Debt -33.9m / FCF TTM -158.8m)
Total Stockholder Equity = 245.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -48.60% (Net Income -175.5m / Total Assets 276.6m)
RoE = -71.51% (Net Income TTM -175.5m / Total Stockholder Equity 245.4m)
RoCE = -61.73% (EBIT -170.3m / Capital Employed (Equity 245.4m + L.T.Debt 30.4m))
RoIC = -48.79% (negative operating profit) (NOPAT -134.5m / Invested Capital 275.7m)
WACC = 7.39% (E(74.4m)/V(134.2m) * Re(10.38%) + D(59.9m)/V(134.2m) * Rd(4.65%) * (1-Tc(0.21)))
Discount Rate = 10.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.25%
Fair Price DCF = unknown (Cash Flow -158.8m)
EPS Correlation: 37.35 | EPS CAGR: 46.90% | SUE: 3.75 | # QB: 2
Revenue Correlation: -42.46 | Revenue CAGR: -8.62% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.020 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.86 | Chg30d=+0.536 | Revisions Net=+2 | Growth EPS=+24.1% | Growth Revenue=+0.0%